- The current PD-L1/PD-1 checkpoint inhibitor drug and diagnostic landscape is highly complicated, with its complexity set to still increase as new monotherapies and combination therapies are developed.
- While “PD-L1 harmonization” efforts have demonstrated different immunohistochemistry (IHC) assays to be analytically comparable, the intended use of each assay does not enable these assays to be used interchangeably.
- Flagship Biosciences’ Computational Tissue Analysis (cTA™) platform leverages digital pathology to enable cross-interpretation of multiple tests, allowing for true harmonization in PD-L1 testing.
- A comparison of the different tests with cTA™ demonstrates critical attributes of each test that account for the different interpretations applied to each test in its intended-use setting.
Flagship’s CSO was interviewed by BioCentury to discuss the details and application of the research presented in this poster. Follow the link below to read the full article.
CALIBRATING PD-L1 ARTICLE